Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Cancer Res Clin Oncol ; 117 Suppl 4: S157-63, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1795006

RESUMO

Combination chemotherapy is widely employed in clinical oncology; however, there is no generally accepted model to evaluate individual tumour susceptibility to a given drug combination protocol. We therefore investigated the drug interaction of ifosfamide (4-hydroxyperoxy-ifosfamide) and ACNU in a recently developed in vitro model of paired sequential combination chemotherapy in primary and metastatic malignant brain tumours. A long-term standard [6,3-3H]-thymidine-incorporation assay, employing a liquid scintillation counting protocol, was selected to assess the drug sensitivity of human tumours. In vitro drug exposures were derived from correlating in vivo-(systemic and CNS) and in vitro-pharmacokinetic drug parameters. In combination experiments tumour cells were treated sequentially by two drugs in both sequences: drug exposures were calculated for 2 h with a 1-h drug-free interval in between. "Cut-off" concentrations (maximum in vitro exposure doses) were calculated as 1.74 microM (for primary CNS tumours: 0.58 microM) for ifosfamide and 5.4 microM (for primary CNS tumours: 1.33 microM) for ACNU. Dose/response relations were derived from isotope incorporation rates after cells had grown for approximately five population doubling times. Combination isoboles were plotted after drug doses had been transformed into "equieffective doses", enabling comparison of drug combination effects. In all three glioblastomas (with CNS exposure dose) an additive or supra-additive effect could be observed in either sequence (in one tumour a biphasic additive isobole was found for both sequences). Out of three bronchial carcinomas (small-cell type, brain metastases) in two non-identical sequences a supra-additive effect was observed in two tumours, with antagonistic effects in the third tumour. In all three malignant melanomas and in one renal carcinoma antagonistic effects were observed, whereas in a second renal carcinoma supra-additive effects were demonstrated for both sequences. We conclude that drug combination chemotherapy effects at the cellular level may be extremely heterogeneous.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Ifosfamida/farmacologia , Nimustina/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/química , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/secundário , Interações Medicamentosas , Humanos , Ifosfamida/administração & dosagem , Nimustina/administração & dosagem , Células Tumorais Cultivadas
2.
Cancer Res ; 50(21): 6981-6, 1990 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-2208165

RESUMO

Autocrine-secreted melanoma tumor growth-inhibiting activity (MIA, approximately Mr 8000) was isolated from supernatants of a malignant melanoma cell line HTZ-19 dM, established from a central nervous system-melanoma metastasis. Cell cycle kinetic analysis performed with bromodeoxyuridine/Hoechst flow cytometry revealed a MIA-sensitive period at the G0/G1 to S traverse; MIA mediated prolongation of the S-phase and increased arrest of cells in the G2 compartment. Growth inhibition by MIA is cell-density dependent; maximal effect is seen at low densities, and the effect may be partially antagonized by whole serum. MIA may cause growth stimulation at high cell densities and low MIA concentrations. The effect of MIA on different histological neuroectodermal cell types was compared by the same methodology: proliferation of a second malignant melanoma was inhibited, and no effect was observed with an ependymoma; 2 glioblastomas were slightly stimulated. Effects on human fibroblast-like cell strains were inconsistent. The mechanism of MIA is discussed in relation to other endogenous autocrine growth inhibitors.


Assuntos
Divisão Celular/efeitos dos fármacos , Inibidores do Crescimento/farmacologia , Melanoma/patologia , Fase S/efeitos dos fármacos , Contagem de Células/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Humanos , Cinética , Células Tumorais Cultivadas
3.
J Dairy Sci ; 68(10): 2694-702, 1985 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-4067038

RESUMO

Six cows were exposed during milkings to electrical current to assess its effects on behavior, health, milking performance, and endocrine responses. Three treatments (0, 4, and 8 mA) were applied in a changeover design over three consecutive 1-wk periods. A cow received the same current treatment during 14 consecutive milkings, beginning with the evening milking (d 1) and ending with the morning milking (d 8). Treatments began 5 min before milking and continued until milking unit removal. Treatments consisted of 60 Hz square wave current of 5-s duration applied every 30 s from udder to hooves. Milk accumulation curves provided information about milk yields, milking times, peak milk flow rates, and times of peak milk flow. Residual milk yields also were measured. Milk was analyzed for protein, fat, and somatic cells. Blood samples from 60 min before to 60 min after treatment were collected, and oxytocin, prolactin, and cortisol concentrations were measured. Behavioral responses to current decreased with time. Changes of milking performance and milk composition were not significant. Changes of milking related cortisol responses during 8-mA current stimulation were significant. Oxytocin release was delayed during 8-mA treatments. Current treatments did not affect prolactin.


Assuntos
Comportamento Animal/fisiologia , Bovinos/fisiologia , Eletricidade/efeitos adversos , Lactação , Leite/análise , Animais , Feminino , Hidrocortisona/sangue , Ocitocina/sangue , Gravidez , Prolactina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...